Argenx
ARGX
#483
Rank
A$73.99 B
Marketcap
A$1,177
Share price
-0.73%
Change (1 day)
-4.37%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): A$23.66

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$22.71. In 2025 the company made an earnings per share (EPS) of A$30.28 an increase over its 2024 EPS that were of A$20.00.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$23.66-21.86%
2025A$30.2851.44%
2024A$20.00-369.77%
2023A-$7.41-60.46%
2022A-$18.7563.33%
2021A-$11.48-40.37%
2020A-$19.25183.47%
2019A-$6.79123.09%
2018A-$3.0454.93%
2017A-$1.9614.07%
2016A-$1.7213.05%
2015A-$1.52-36.34%
2014A-$2.39209.04%
2013A-$0.77-33.99%
2012A-$1.17185.59%
2011A-$0.41